target
-
Salix initiates Target 3 phase 3 study
Salix initiates Target 3 phase 3 study to assess repeat treatment efficacy and safety of Rifaximin 550MG TID in subjects with irritable bowel syndrome with diarrhea
target | 06 April 2012
-
apceth, Indivumed to develop biomarker platform for targeted cellular therapies
apceth and Indivumed have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
target | 27 March 2012
-
Agilent Technologies extends target-enrichment platform to desktop sequencers
Agilent Technologies expanded its SureSelect target-enrichment system with the HaloPlex target enrichment system for desktop sequencers.
target | 12 March 2012
-
Agilent Technologies introduces DNA methylation target-enrichment system
Agilent Technologies expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites. It is the first comprehensive DNA methylation discovery system using target enrichment.
target | 27 February 2012
-
Agilent Technologies signs agreement to supply target enrichment system to Ambry Genetics
Agilent Technologies and Ambry Genetics announced an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services.
target | 31 October 2011
-
AstraZeneca, Heptares to investigate important GPCR drug targets
AstraZeneca and Heptares Therapeutics announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most imp…
target | 31 May 2011
-
Agilent appoints Beckman as CSP for target enrichment and microarrays
Beckman Coulter Genomics has achieved Certified Service Provider (CSP) status for the Agilent SureSelect Target Enrichment System, including SureSelect XT which combines sequencing library preparation and gDNA preparative reagents. Through its a…
target | 11 January 2011
-
Addressing multiple disease targets with single protein therapy
Selexis entered into strategic agreement with Zyngenia under which Selexis will utilize its' SURE cell line development platform to generate production cell lines for Zyngenia’s lead Zybody therapeutic programs. â€We are excited to support Zy…
target | 03 December 2010
-
Human exon target enrichment tool
Agilent Technologies’ SureSelect human all exon v2 target enrichment kit was developed in collaboration with the Broad Institute of MIT and Harvard. The kit, the 15th SureSelect product in Agilent’s portfolio, is a single tube assay that allows …
target | 13 November 2010
-
Growth of cancer targeted therapies and immunotherapies
Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst Datamonitor. Over the l…
target | 01 October 2010
